Magazine Article | May 2, 2022

Are Cannabinoids The Next Blockbuster Drugs? A Q&A With Jazz Pharma's CEO Bruce Cozadd

Source: Life Science Leader

By Ben Comer, Chief Editor, Life Science Leader

Jazz Pharmaceuticals’ $7.2 billion acquisition of GW Pharmaceuticals in 2021 nearly doubled the company’s headcount and placed it at the vanguard of cannabinoid companies. With the FDA approval of Epidiolex (cannabidiol) in 2018, GW Pharma became the first company to bring a prescription drug derived from marijuana plants to market.

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: